Oryzon Genomics SA

Oryzon Genomics is a publicly traded, clinical-stage biopharmaceutical company with a European leadership position in developing epigenetics-based therapeutics. The company specializes in personalized medicine approaches to treat Central Nervous System (CNS) disorders and cancer, leveraging its expertise in the field of LSD1 inhibition. Oryzon boasts a strong intellectual property portfolio and a growing pipeline of drug candidates, with two compounds currently in Phase II clinical trials.

Oryzon's business model is to develop its proprietary drug candidates through clinical Phase II, at which point the company decides on a case-by-case basis whether to keep the development in-house or partner with other pharmaceutical companies for late-stage development and commercialization. The company has offices in Spain and the United States, and has attracted specialized investors from across the globe.

Oryzon Genomics SA is a clinical-stage biopharmaceutical company focused on developing innovative, epigenetic, personalized medicines for patients with cancer and central nervous system (CNS) disorders. Their mission is to leverage the power of epigenetics to discover and develop groundbreaking therapies that address the unique needs of individual patients, ultimately improving their lives and outcomes.

Oryzon Genomics cultivates a culture of innovation and collaboration, driven by passionate biopharma executives who are dedicated to translating epigenetic science into personalized medicines for patients. They foster a collaborative environment among their international teams, prioritizing the development of their proprietary drug candidates through clinical trials. This focus on research and development is supported by a strong intellectual property position and a commitment to personalized medicine approaches.